Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Research on breast cancer reported by A. Gennari et al
June 11th, 2009
" This phase II study, evaluated the activity and cardiotoxicity of first-line epirubicin plus low-dose trastuzumab (LD-T) in patients with HER2 positive MBC. Patients received epirubicin 90 mg/sqm every 3 weeks plus weekly LD-T (2 mg/kg loading dose, then 1 mg/kg)," scientists writing in the journal Breast Cancer Research and Treatment report. "After 6/8 cycles of epirubicin, single agent trastuzumab was continued. Cardiotoxicity was defined as signs or symptoms of congestive heart failure (CHF), or a parts per thousand yen15% decline in LVEF without symptoms, or < 15% LVEF decline to less than 50%, without symptoms. Forty-five patients were enrolled....
Source: Women's Health Weekly (2009-06-11)
|
